Volume Rebounds, Margins Collapse: Supreme Petrochem's Macro Tether
Reported profit doubled year-on-year, but profit plunged 59% quarter-on-quarter as raw material costs swamped pricing power. The market's lukewarm reception signals the real risk: growth is hostage to geopolitical and raw material stability, not execution.
₹97.1 Cr
+100.4% YoY
-59% QoQ
₹97.1 Cr vs ~₹237 Cr
9.08%
₹331 Cr on ₹3,649 Cr
4.9%
-4.18 ppts from H1
Supreme Petrochem's Q2 reads as two opposite stories. The headline is blazing: revenue ₹1,984 crore, up 77.5% year-on-year, and profit ₹97.1 crore, up 100%. Volumes rebounded 24% year-on-year after a -24.5% crater in Q1. But the quarter-on-quarter view exposes the fragility. Profit plunged 59% from Q1 (implied ₹237 crore), and net margin compressed from 9.08% in H1 to just 4.9% in Q2. This margin cliff is not operational slippage — it is raw material cost pass-through lag. Styrene monomer nearly doubled ($900 to $1,650+) in the past year. Inventory marked to market at higher costs, but the sell-through of those costs into customer contracts lagged. The result: reported profit grew year-on-year, but operating quality deteriorated quarter-on-quarter.
Where profit momentum broke
H1 PAT of ₹331 crore implies Q1 profit around ₹234–237 crore. The Q2 print of ₹97.1 crore is a drop of ₹136–140 crore sequentially. Management attributed this to raw material cost pass-through lag. Styrene spot prices spiked 83% ($900 to $1,650+) over the year, and inventory surged ~50% year-on-year. While SAP marks inventory to market in real time, there is an inherent lag between the purchase price, the cost-of-goods-sold recognition, and the customer contract repricing. October consumption is expected to digest much of the overages, but the timing risk is real. Additionally, Q2 benefited from duty-free imports of polystyrene and ABS (a May–July exemption that ended in July), which temporarily inflated topline while margin contribution was modest. Once the exemption lapsed, competitive pressure normalized. Trading sales — forex and commodity hedges — represented ~22% of Q2 topline, inflating reported revenue without corresponding operating earnings.
Claims on the call vs. what holds up
Q2 operating income ₹1,957 Cr vs ₹1,100 Cr YoY (77.8% growth)
Delivered Q2 revenue ₹1,983.5 Cr; YoY growth 77.5%. Operating income not separately disclosed but revenue aligns.
Supported
Q2 PAT ₹95 Cr with margins compressing as raw material prices normalize
Delivered PAT ₹97.1 Cr (off by ₹2 Cr). H1 margin 9.08%, Q2 margin 4.9%. Compression proven.
Supported
Q2 volumes +24% YoY, +35% QoQ
Q2 volume 95,242 MT. Rebound after Q1 ~80,843 MT (-24.5%) aligns. H1 volumes -3% YoY despite Q2 rebound.
Supported (but H1 overall still down YoY)
ABS at 65% of rated capacity, 85% of truncated capacity utilized
Equipment damage history acknowledged; repair timeline unspecified. Capacity constraint confirmed but recovery trajectory vague.
Supported (but underutilized vs. nameplate)
₹450 Cr capex (ABS by June 2027, polystyrene by Dec 2028) on track
Reaffirmed in call. ABS phase-1 targeting 70k tons by Q3 FY28; phase-2 80k tons total by Q3 FY28. No budget or timeline revision.
Supported (execution risk remains)
What changed this quarter
Volume trajectory upgraded: Q1 -24.5% → Q2 +24% YoY; H1 still -3% but inflection clear
Margin guidance ('will compress') proven accurate; no recovery target set
Specialty compound mix accelerating: PES/ABS volumes +172% H1; now 40% of sales vs 30–35% prior
Capex pipeline concrete (ABS phase-1 & phase-2, XPS Q1 FY28); no revision needed
Export headwinds persist: H1 volumes -3% YoY despite Q2 rebound; freight/geopolitical overhang ongoing
No FY27 quantified guidance offered (prior 8–10% volume guidance abandoned Q1)
The bull-bear ledger
YoY profit doubled (+100%) and revenue surged (+77.5%); volume recovery momentum is real
Debt-free balance sheet (₹886 crore surplus Sep 2026) funds ₹450 Cr capex internally; no capital constraint
Specialty mix uplift (40% of sales) and new applications (battery, auto components) diversifying revenue
Capex timeline concrete and on track; ABS ramp (70k→80k tons by Q3 FY28) and XPS (Q1 FY28) visible
Polystyrene market leadership (60% India market share); appliance/AC boom structural tailwind
QoQ margin collapse (-59% PAT, 4.9% NPM vs 9.08%) signals near-term vulnerability to raw material swings
Styrene cost doubled ($900→$1,650+); pass-through lag and inventory carry-cost embedded; no margin floor set
Management offers no FY27 revenue or margin target; hedged 'very difficult to predict' tone on recovery
ABS equipment damage history (65% of rated capacity) constrains near-term growth; repair timeline vague
Export recovery contingent on US elections, geopolitical thaw, freight normalization; H1 volumes -3% YoY
Trading sales (~22% of Q2) and duty-free import benefit (May–July) are one-time topline inflators
Capex execution risk: ABS phase overlap, equipment history, timeline slippage could delay ROI
Risks, ranked by how much they should concern a holder
Raw material cost pass-through lag
HighStyrene doubled ($900→$1,650+). Inventory lag creates temporary margin troughs. Q2 NPM 4.9% vs H1 9.08% proves it. Recovery hinges on customer repricing and consumption timing, not execution.
Geopolitical dependency for growth
HighManagement explicitly caveated Q3–Q4 FY27 outlook on US elections, war clouds, shipping normalization. No quantified FY27 target; hedged 'very difficult to predict'. Growth visibility is low-conviction unless macro stabilizes.
Export headwind persistence
HighH1 volumes -3% YoY despite Q2 rebound. Management cited volatile raw material prices, freight spikes, order-to-shipment lag. No export recovery timeline given. Domestic-only scenario weighs on CAGR.
Capex execution risk (ABS equipment history)
MediumABS line equipment damage unresolved (65% of rated capacity, 85% of truncated utilized). Phase-1 70k tons by Q3 FY28 and phase-2 80k tons timeline critical to capex ROI. Delay compounds revenue and margin risk.
Competitive capacity & import pressure
MediumDomestic competitors adding ABS capacity (pipeline). Duty-free imports pressured Q2 pricing (May–July exemption). Once exemption ended, pricing normalized, but competitive dynamics remain. Market share erosion risk if incumbent capacity comes online.
Inventory carry-cost reversal
MediumInventory surged ~50% YoY at higher raw material costs. SAP marks to market, but consumption throughout month creates lag. October month-end reversal may create timing benefit, but Q3 baseline lower if raw material prices stabilize.
How the street is positioned
Supreme Petrochem's stock price is ₹680 as of Oct 30, 2026 — 30.5% below its all-time high and trading below all major moving averages (SMA20 ₹756, SMA50 ₹772, SMA200 ₹708). The RSI of 29 signals an oversold condition. Yet the result announcement did not spark a relief rally. The stock fell 0.45% on day 1, bounced +1.53% by day 3, then faded to -4.57% by day 5 — a net negative verdict from the market. This reaction is telling: despite profit doubling year-on-year, the market marked the quarter as disappointing. The mismatch between reported YoY growth and the sell-off suggests the street is pricing in execution risk and macro sensitivity, not celebrating topline growth. Foreign institutional investors (FII) are stable at 3.80% (up 11bp quarter-on-quarter), domestic institutions (DII) flat at 4.14% (down 10bp), and the promoter unchanged at 64.24%. No panic selling, but no institution buying the dip either. The stock's drawdown from ATH combined with a weak post-result tape implies the market is waiting for either margin stabilization (which hinges on raw material prices) or capex catalysts (Q1 FY28 XPS launch, Q3 FY28 ABS phase-2 completion).
The debate
What to watch next
1 · Raw material and freight stabilization (Q3–Q4 FY27)
If styrene monomer prices stabilize ≤$1,500 and ocean freight normalizes post US elections, inventory carry-costs will unwind and gross margins can revert toward Q2 spreads (GIPS $200–250, HIPS $300–350) or better. Watch Q3 and Q4 reported margins. If NPM remains <5.5%, the pass-through remains incomplete and geopolitical risk is real.
2 · ABS phase-1 execution by Q3 FY28 (target 70k tons)
The capex story hinges on whether management can ramp ABS from 65% of rated (or 85% of truncated) to 70k tons on schedule. Equipment repair must complete, phase-1 and phase-2 must not conflict. If timeline slips into Q4 FY28 or later, capex ROI deteriorates and near-term profit ramps are pushed out.
3 · Export recovery (H2 FY27, Oct 2026–Mar 2027)
H1 volumes are -3% YoY. Q2 showed some non-OEM recovery but still subdued. If Q3–Q4 export volumes rebound (freight normalizes, geopolitical risk subsides), H1 baseline recovery is possible. If exports remain flat or decline, the story is domestic-only and growth capped at 10–15% (appliance + specialty + Xmold).
Supreme Petrochem is not a broken story — profit doubled year-on-year, volumes rebounded sharply, and capex is funded and on track. But it is a story in suspension. The quarter-on-quarter margin collapse (-59% PAT, 4.9% NPM) is a reminder that near-term profit is hostage to raw material and freight, not to sales execution. Management's refusal to quantify FY27 guidance and its explicit hedging on geopolitical recovery signal that visibility is genuinely low. The capex pipeline (ABS, XPS, compounding) is credible, but ramp timelines and market absorption are multi-year questions. The stock's 30% drawdown and weak post-result tape reflect this uncertainty.
Hold. The debate will resolve in H2 FY27. If raw material prices stabilize and export recovery materializes, margin and volume momentum will both improve — capex story unlocks and near-term P&L becomes less hostage to macro. If geopolitical headwinds persist and margins stay compressed, capex execution becomes the only lever, and near-term returns are muted. Track Q3 and Q4 reported margin (the organic number to watch from here) and H2 export volumes (the growth normalcy signal).
Informational and educational content only. Not investment advice.